Wearable Devices Empowering Active Health Initiatives for High-Risk Stroke Populations
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- medication adherence and risk factor control rates
研究概览
简要总结
The purpose of this study is to evaluate the control effect of smart wearable devices on key risk factors in the high-risk populations for stroke
详细描述
A randomized controlled study was conducted on the application of smart wearable devices in the intervention of high-risk populations for stroke, with a focus on whether the functions of smart wearable devices such as medication reminders, heart rate monitoring, and exercise reminders can effectively benefit the improvement of key risk factors for stroke, especially blood pressure, blood glucose, and blood lipids.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with hypertension;
- •Diagnosed with diabetes;
- •Diagnosed with atrial fibrillation;
- •Smoking subjects;
- •Physical inactive subjects；
- •Obesity and overweight subjects;
- •Must be able to use smart wearable devices.
排除标准
- •Diagnosed with malignancies;
- •Diagnosed with psychiatric disorders;
- •Diagnosed with cognitive impairment;
- •Unable to operate smart wearable devices.
研究组 & 干预措施
With Wearable Devices
Participants utilize wearable devices (smart wristbands) 24 hours a day for 6 months and receive medication reminders for each use and heart rate monitoring.
干预措施: Wearable Devices (Behavioral)
Without Wearable Devices
Participants do not utilize wearable devices (smart wristbands) .
结局指标
主要结局
medication adherence and risk factor control rates
时间窗: 6 months
1.The medication rates and control rates for hypertension; 2.The medication rates and control rates for hyperglycemia; 3. The medication rates and control rates for hyperlipidemia; 4.The medication rates and control rates for obesity.
次要结局
- incident vascular events, including stroke, coronary heart disease (CHD), peripheral vascular disease (PVD), and other related cardiovascular events(6 months)